Sector News

Eli Lilly, Amgen join forces to scale production of COVID-19 antibody cocktails

September 18, 2020
Life sciences

Months of fervid research have whittled away most potential options to treat patients with COVID-19, a group of antibody cocktails still hold promise. Eli Lilly believes so strongly in its contender that it’s bringing on a major pharma partner to chip in on production.

Eli LIlly and Amgen have teamed up to scale manufacturing of future antibody cocktails, including Lilly’s LY-CoV-55, in testing to treat COVID-19, the partners said Thursday.

In a joint statement slim on details, both drugmakers pledged only to “quickly scale up production” of a range of neutralizing antibodies Lilly is studying to treat COVID-19—if any get over the regulatory finish line, that is.

The most promising of those candidates is LY-CoV-555, an AbCellera-partnered cocktail that entered phase 3 human testing in August. Lilly is also developing LY-CoV016 through a licensing deal with China’s Junshi Biosciences and has launched a phase 2 trial testing a combination of the two in patients with early, mild to moderate COVID-19.

An Amgen spokesman declined in an email to offer further details on the deal.

So far, Lilly’s lead antibody candidate has shown mixed promise in human tests, with data from a phase 2 trial release this week showing two of three tested doses didn’t top placebo in reducing patients’ viral load at the 11-day mark.

Only the 2,800-milligram dose met the primary endpoint. The other two doses—700 milligrams and 7,000 milligrams—did no better than placebo. Typically, the highest dose of a drug has the biggest effect.

It’s not the first time during the novel coronavirus pandemic that Lilly and Amgen have combined forces to boost COVID-fighting antibodies.

In late June, both drugmakers joined a brain trust alongside AstraZeneca, GlaxoSmithKline, Roche’s Genentech and AbCellera to share monoclonal antibody manufacturing secrets in an effort to get each member up to speed on manufacturing best practices.

The unusual arrangement won the backing of the Department of Justice’s antitrust division, which said in a statement at the time that all six drugmakers wouldn’t be allowed to discuss pricing as part of their collab.

The deal notably didn’t include Regeneron and its advanced antibody cocktail, which carries sales hopes of $6 billion per year after the New York drugmaker reached an expansive global manufacturing tie-up with Roche in August.

Alongside its own antibody aims, Lilly has found a foothold in repurposing rheumatoid arthritis med Olumiant to treat COVID-19. The med, added to Gilead’s Veklury (remdesivir), posted promising trial results earlier this week.

In data unveiled Monday, patients treated with with an Olumiant-Veklury combo recovered faster than those on Gilead’s drug alone. The difference was about one day at the median, significant enough to prompt Lilly to take the data to the FDA for a possible emergency approval.

If Olumiant succeeds, it would become the third therapy with an early approval to treat COVID-19 alongside Veklury and convalescent plasma.

By: Kyle Blankenship

Source: Fierce Pharma

comments closed

Related News

January 22, 2023

Sun Pharma to buy Concert Pharmaceuticals for $576m

Life sciences

Sun Pharmaceutical Industries has signed a definitive agreement to buy all outstanding shares of Concert Pharmaceuticals in a deal valued at $576m. Under the deal, the company will buy all shares of Concert common stock through a tender offer for $8.00 per share in cash upfront payment.

January 22, 2023

Novo Nordisk diabetes pill wins FDA approval for first-line use

Life sciences

The Food and Drug Administration on Thursday approved Novo Nordisk’s diabetes pill Rybelsus as an initial treatment to lower blood sugar levels, a label expansion that will allow it to compete more directly with other oral drugs from Merck & Co. and Eli Lilly.

January 22, 2023

Bayer feeling more heat from activist investors, this time from Bluebell

Life sciences

Since making an ill-advised $63 billion buy of Monsanto in 2018, Bayer has faced heaps of pressure from investors that have called for the company to oust its leadership and to restructure. Now comes new pressure from a familiar source. Bluebell Capital Partners has bought an undisclosed stake in the company and is agitating for a breakup, sources told Reuters.

How can we help you?

We're easy to reach